DI
ABUS icon

DAGCO Inc’s Arbutus Biopharma ABUS Stock Holding History

DAGCO Inc’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,300
Closed -$15.8K – 221
2023
Q4 		$15.8K Buy
+6,300
New +$12.3K 0.01% 183

Other funds holding ABUS

WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAGCO Inc's ABUS Position: Q1 2024 in Review

DAGCO Inc sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 6,300 shares — an estimated $15.8K sold.

DAGCO Inc first reported a position in ABUS in Q4 2023 and held it in 1 quarter. The position peaked at $15.8K in Q4 2023. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

  • DAGCO Inc reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
  • DAGCO Inc sold 6,300 Arbutus Biopharma shares in Q1 2024, an estimated $15.8K.
  • DAGCO Inc first reported a position in Arbutus Biopharma in Q4 2023 and held it in 1 quarter.
  • DAGCO Inc's Arbutus Biopharma position peaked at $15.8K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.